Clinical trial · Interventional
Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension
A Randomized, Double-blind, Placebo-controlled Study of Megestrol Acetate Concentrated Suspension for the Treatment of Cancer-associated Anorexia in Subjects With Cancer of Multiple Types
NCT00637806CI-TRIAL-00021975terminatedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Difficulty finding the required patient population
Summary
Brief summary (as posted)
To compare the effect of megestrol acetate concentrated suspension and placebo on caloric intake in patients with cancer-associated anorexia.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anorexia | — | UNRESOLVED | — |
| Cachexia | — | UNRESOLVED | — |
| Weight Loss | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Megestrol acetate concentrated suspension 110 mg/mL | Drug | — | UNRESOLVED |
| Megestrol acetate concentrated suspension 60 mg/mL | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- 1
- description
- Megestrol acetate concentrated suspension 110 mg/mL
- interventionNames
- Drug: Megestrol acetate concentrated suspension 110 mg/mL
- type
- ACTIVE_COMPARATOR
- label
- 2
- description
- Megestrol acetate concentrated suspension 60 mg/mL
- interventionNames
- Drug: Megestrol acetate concentrated suspension 60 mg/mL
- type
- PLACEBO_COMPARATOR
- label
- 3
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer of multiple types in stage II, III, or IV and not a candidate for chemotherapy; but may have been receiving radiation therapy * Fair, poor, or very poor appetite * Cancer-associated anorexia/cachexia (documented weight loss of 2% over the prior week, or at least 5% within past 30 days, or at least 7.5% over prior 3 months, or at least 10% over prior 6 months) * Weight loss perceived to be associated with diminished appetite * Eastern Cooperative Oncology Group Performance score of 0, 1, or 2 * Life expectancy greater than 3 months * Alert and mentally competent to complete study assessments * Women of child-bearing potential required to use an adequate and reliable method of contraception. Post-menopausal women have to have been so for at least 1 year * Screening laboratory values must not be clinically significant (some exceptions per protocol) Exclusion Criteria: * Brain, or head and neck tumors that may interfere with food consumption * AIDS-related wasting * Radiation therapy to head and neck, abdomen, or pelvis within past 6 weeks, or for whom radiation therapy is anticipated during the study such that the result may interfere with food consumption * Presence of conditions that interfere with oral intake or ability to swallow * Absence of normally functioning gut * Known mechanical obstruction of the alimentary or biliary tract, or malabsorption syndrome * Intractable or frequent vomiting * Clinically significant diarrhea * History of thromboembolic events, or on long-term anticoagulation for thromboembolism * Uncontrolled diabetes mellitus, or symptomatic hypoadrenalism * Poorly controlled hypertension or congestive heart failure * Pregnant/lactating females, or planning on becoming pregnant * Use of appetite stimulants within past 30 days * Use of parenteral nutrition or tube feedings within past 1 week * Chronic use of steroids within past 3 months (intermittent short-term use allowed) * Current use of illicit substances * Allergy, hypersensitivity, or other contraindication to megestrol acetate
References
Publications (0)
Data not yet available
No reference posted for this study.